AstraZeneca - Current status and future directions for immunotherapy in hepatocellular carcinoma
Welcome and introduction
Date
14 Sep 2020Session
AstraZeneca - Current status and future directions for immunotherapy in hepatocellular carcinomaPresenters
Ghassan Abou-AlfaAuthors
G.K. Abou-AlfaAuthor affiliations
- Medicine Department, Memorial Sloan Kettering Evelyn H. Lauder Breast Center, 10065 - New York/US
Resources
Resources from the same session
Brief overview of immuno-oncology in HCC
Presenter: Ghassan Abou-Alfa
Session: AstraZeneca - Current status and future directions for immunotherapy in hepatocellular carcinoma
Resources:
Webcast
IO combinations in first-line advanced HCC: Current evidence and ongoing trials
Presenter: Peter Galle
Session: AstraZeneca - Current status and future directions for immunotherapy in hepatocellular carcinoma
Resources:
Webcast
IO combinations early or intermediate-stage HCC: Current evidence and ongoing trials
Presenter: Ghassan Abou-Alfa
Session: AstraZeneca - Current status and future directions for immunotherapy in hepatocellular carcinoma
Resources:
Webcast
Putting it all together: Case discussions
Presenter: Bruno Sangro
Session: AstraZeneca - Current status and future directions for immunotherapy in hepatocellular carcinoma
Resources:
Webcast
Summary, final thoughts, and audience question and answer session
Presenter: Ghassan Abou-Alfa
Session: AstraZeneca - Current status and future directions for immunotherapy in hepatocellular carcinoma
Resources:
Webcast